H8H-MC-LAHX

A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Pediatric Patients with Migraine

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224864

Enrollment

Registered

2019-09-11

Start date

2019-08-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

investigational material(s) Generic name etc : Lasmiditan INN of investigational material : Lasmiditan Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Participants must have a history of migraine headaches for more than 6 months -Participants must have a history of 2 to 15 migraine headaches per month in the past 2 months -Participants must weigh between 15 and 55 kilograms (kg) -Participants must not have a migraine headache on the day of lasmiditan administration

Exclusion criteria

Exclusion criteria: -Participants must not be pregnant or nursing -Participants must not have any acute, serious, or unstable medical condition -Participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator -Participants must not be on a medicine that acts in the brain and spinal cord

Design outcomes

Primary

Measure	Time frame
pharmacokinetics Pharmacokinetics of Lasmiditan in pediatric migraine patients following a single oral dose of lasmiditan.	—

Secondary

Measure	Time frame
safety other Safety and Tolerability of Lasmiditan in pediatric migraine patients following a single oral dose of lasmiditan.	—

Countries

Japan, North America

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026